Conventional antifungal therapy for fungal endocarditis has been associated with a poor cure rate. Therefore, combined medical and surgical therapy has been recommended. However, new potent antifungal agents, such as echinocandins, could increase the medical options and, in some cases, avoid the need for surgery. We report a case of Candida endocarditis treated successfully without valve replacement with intravenous liposomal amphotericin B (total dose, 4 g) and intravenous caspofungin (a 100-mg loading dose followed by 50 mg per day for 8 weeks) as induction therapy and intravenous caspofungin (100 mg 3 times per week for 12 weeks) as maintenance therapy.
Fungal endocarditis is an uncommon infection associated with considerable morbidity and mortality. The number of cases has increased during the past 2 decades, and fungi now comprise 1%-10% of organisms isolated in patients with infective endocarditis [1] , including ∼10% of those patients with prosthetic valve endocarditis [2] . The difficulty in sterilizing vegetations, the high percentage of embolic phenomena, and the predilection for prosthetic valves have led to the paradigm that all patients with fungal endocarditis should be treated with combined medical and surgical therapy. However, the evidence for these recommendations primarily involves expert opinion, and therefore, the optimal algorithm for the treatment of fungal endocarditis is still uncertain. This report describes a patient with Candida endocarditis treated successfully with antifungal therapy alone.
Case report. An 84-year-old woman with a history of relapsing urinary tract infection presented to an outside hospital on 28 November 2002 after 1 week of fever (temperature, 38.5ЊC), chills, and vomiting. The findings of a physical examination were normal. Three blood samples were obtained for culture, and the patient was discharged without receiving treatment. The fever resolved after 72 h, and the patient remained without symptoms. One week later, she was readmitted to the hospital because of fever. Physical examination revealed a new systolic cardiac murmur. Laboratory testing revealed leukocytosis, an elevated erythrocyte sedimentation rate (46 mm/h), and a C-reactive protein level of 6.6 mg/dL. All blood cultures, including those of samples obtained during her first hospitalization, yielded Candida glabrata. Transthoracic echocardiography revealed mitral calcification with severe regurgitation, as well as the presence of a mitral vegetation on the posterior leaflet. The patient was transferred to Hospital Clinic, Barcelona, Spain.
At the time of admission to our health care center (20 December 2002), 2 new blood samples were obtained for culture, and transesophageal echocardiography was performed. Blood cultures again yielded C. glabrata , and transesophageal echocardiography revealed severe mitral regurgitation secondary to anterior leaflet perforation, with a mobile vegetation (diameter, 3 mm), as well as severe aortic regurgitation. Neither paravalvular abscesses nor intracardiac fistulae were observed. Because the patient was hemodynamically stable and considered to be a poor surgical candidate, aggressive medical therapy was initiated.
Antifungal susceptibilities were determined on the basis of NCCLS recommendations for broth macrodilution and microdilution testing [3] . The following MICs were determined: amphotericin B, 0.5 mg/mL; flucytosine, р0.06 mg/mL; voriconazole, 0.5 mg/mL; caspofungin, 0.125 mg/mL; and fluconazole, 32 mg/mL. Therapy with intravenous liposomal amphotericin B (3 mg/kg q.d.) plus caspofungin (a 100-mg loading dose, followed by a maintenance dosage of 50 mg q.d.) was prescribed. After 3 weeks, the amphotericin B component of therapy was stopped (total cumulative dose, 4 g), and treatment with caspofungin alone was continued a total of 8 weeks. Caspofungin concentrations, which were determined by bioassay [4] , were 4-6 mg/mL before dosing and 16 mg/mL after dosing. Both antifungal drugs were well tolerated. Caspofungin concentrations during this regimen were as follows: 4 mg/mL (predose, trough) after 2 days, 3 mg/mL (predose, trough) after 3 days, and 15-16mg/mL (postdose). In October 2003, the patient was admitted to the hospital with mild-to-moderate left-side heart failure, but she responded rapidly to medical management. Nine months after she stopped receiving all antifungal therapy, the patient was stable and without evidence of recurrence. No systemic emboli were observed throughout her illness, and blood cultures performed at 3, 6, and 9 months after treatment were sterile. Table 1 summarizes the laboratory and echocardiographic findings and the antifungal treatment given over the course of her disease.
Discussion. Fungal endocarditis is a difficult disease to treat effectively. Medical therapy alone has been associated with a poor cure rate. A combined medical and surgical approach seems to be associated with an improved outcome and, therefore, has been the recommended form of treatment [5, 6] . The reasons for this recommendation are several: the risk of embolization, the difficulty in sterilizing large fungal vegetations, and the high mortality rate associated with medical therapy alone [7] . However, the recommendation for universal valve replacement is controversial for the following reasons: (1) because of the low incidence of Candida endocarditis, the evidence for this recommendation is derived from individual case reports and case series; (2) some authors have reported cases of Candida endocarditis that have been treated successfully with combined antifungal therapy alone [8] ; (3) there are some data indicating that surgical intervention did not improve outcome, compared with medical therapy alone, in patients with uncomplicated Candida prosthetic valve endocarditis [9] ; and (4) some patients are poor candidates for surgery.
Conventional medical therapy for Candida endocarditis consists of intravenous amphotericin B (with or without oral flucytosine) or fluconazole alone, although fluconazole is most often administered as long-term suppressive therapy. The total duration of therapy is recommended to be from 6 weeks to years, with long-term follow-up, as Candida endocarditis has a propensity to relapse [10] . However, several factors may limit the efficacy of the actual therapeutic regimens: the poor penetration of antifungal agents into vegetations [11] , the low toxic-therapeutic ratio of the available antifungal agents, and the lack of fungicidal activity with these antifungals.
The recent availability of more-potent and less-toxic antifungal agents, such as the echinocandins, could increase the medical options for Candida endocarditis. The echinocandins are new antifungals, which inhibit the b-(1,3)-glucan synthesis, an action that damages fungal cell walls. They are fungicidal in vitro and in vivo against most isolates of Candida species, including C. glabrata , and have a benign toxicity profile [12] . In addition, caspofungin, one of the echinocandin antifungal agents, has shown excellent activity against Candida biofilm [13] .
Because our patient was considered a poor candidate for surgery, an antifungal regimen alone was prescribed. Treatment included a combination of liposomal amphotericin B plus caspofungin, because there are some data to suggest that the effect of these agents may be synergistic [14] . Likewise, caspofungin was prescribed as long-term suppressive therapy because the C. glabrata isolated was resistant to fluconazole and because of toxicity associated with voriconazole. In contrast, caspofungin shows an excellent safety profile and was well tolerated. Caspofungin was administered 3 days per week on the basis of its pharmacokinetic properties, with plasma concentrations declining in a polyphasic manner (a-phase, immediately following administration; and b-phase that exhibited log-linear behavior from 6-48 h after administration, with a half-life of 9-11 h) [15] . This report suggests that selected patients with fungal endocarditis may be treated with antifungal therapy alone. The efficacy and safety of caspofungin make this drug an ideal agent for the future trials on the treatment of Candida endocarditis.
